Tiroidite autoimmune
La tiroidite autoimmune è la malattia caratterizzata dalla presenza di Autoanticorpi Anti PEROSSIDASI (AbTPO) e Autoanticorpi Anti TIREOGLOBULINA (AbTG) che danneggiano la tiroide determinando un ipotiroidismo clinico con insorgenza di FACILE STAMCABILITA’ DEPRESSIONE – AUMENTO di PESO – e nei casi più gravi ALTERAZIONI del CICLO MESTRUALE e CADUTA dei CAPELLI. La malattia può decorrere per molti anni con valori di FT4 – FT3 – TSH del tutto normali e rivelarsi soltanto attraverso il dosaggio degli anticorpi specifici e dell’esame ecografico color doppler che in mani esperte è diagnostico di malattia autoimmune tiroidea evidenziando la caratteristica IPO - ecogenicità parenchimale a “zolle” o a “pelle di leopardo”.
Bibiografia:
Bianco AC. Maia AL. da Silva WS. Christoffolete MA. Adaptive activation of thyroid hormone and energy expenditure. Biosci Rep. 2005;25:191–208.
Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev. 2001;81:1097–1142.
Brent GA. Tissue-specific actions of thyroid hormone: insights from animal models. Rev Endocr Metab Disord. 2000;1:27–33.
Chiellini G. Apriletti JW. Yoshihara HA. Baxter JD. Ribeiro RC. Scanlan TS. A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol. 1998;5:299–306.
Trost SU. Swanson E. Gloss B. Wang-Iverson DB. Zhang H. Volodarsky T. Grover GJ. Baxter JD. Chiellini G. Scanlan TS. Dillmann WH. The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology. 2000;141:3057–3064.
Bryzgalova G. Effendic S. Khan A. Rehnmark S. Barbounis P. Boulet J. Dong G. Singh R. Shapses S. Malm J. Webb P. Baxter JD. Grover GJ. Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141. J Steroid Biochem Mol Biol. 2008;111:262–267.
Erion MD. Cable EE. Ito BR. Jiang H. Fujitaki JM. Finn PD. Zhang BH. Hou J. Boyer SH. van Poelje PD. Linemeyer DL. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci U S A. 2007;104:15490–15495.
Miyabara EH. Aoki MS. Soares AG. Saltao RM. Vilicev CM. Passarelli M. Scanlan TS. Gouveia CH. Moriscot AS. Thyroid hormone receptor-beta-selective agonist GC-24 spares skeletal muscle type I to II fiber shift. Cell Tissue Res. 2005;321:233–241.
Perra A. Simbula G. Simbula M. Pibiri M. Kowalik MA. Sulas P. Cocco MT. Ledda-Columbano GM. Columbano A. Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats. FASEB J. 2008;22:2981–2989.
Grover GJ. Mellstrom K. Malm J. Therapeutic potential for thyroid hormone receptor-beta selective agonists for treating obesity, hyperlipidemia and diabetes. Curr Vasc Pharmacol. 2007;5:141–154.
Villicev CM. Freitas FR. Aoki MS. Taffarel C. Scanlan TS. Moriscot AS. Ribeiro MO. Bianco AC. Gouveia CH. Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats. J Endocrinol. 2007;193:21–29.